NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with Irish Pharmacist includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.


ADVERTISMENT

ADVERTISMENT

LENALIDOMIDE CLONMEL

By Irish Pharmacist - 28th Feb 2022

Clonmel Healthcare is delighted to announce the launch of Lenalidomide Clonmel 5mg, 10mg, 15mg, 20mg, 25mg hard capsules. 

Lenalidomide Clonmel is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma and follicular lymphoma. 

Lenalidomide is structurally related to thalidomide, which is a known human teratogen that causes severe life-threatening birth defects. An unborn child is likely to be harmed if exposed to lenalidomide during pregnancy, therefore a pregnancy prevention programme (PPP) is in place for all lenalidomide products and applies to all patients prescribed lenalidomide. 

In order to support HCPs in fulfilling the requirements of the lenalidomide PPP, Clonmel Healthcare, in collaboration with a number of other marketing authorisations holders, has created an online platform called the Patient Safety Hub (PSH) which may be used by prescribers and pharmacies. It is available at www.patientsafetyhub.ie. 

Pharmacies wishing to purchase and dispense Lenalidomide Clonmel must register via the Patient Safety Hub at www.patientsafetyhub.ie. Registration involves the pharmacy indicating its agreement and compliance with the requirements of the lenalidomide pregnancy prevention programme. 

A user guide and training videos on use of the PSH are also available to access via the hub. 

Full prescribing information is available on request or alternatively, please go to www.clonmel-health. ie. Medicinal product subject to medical prescription. 

Please contact Clonmel Healthcare on 01-6204000 if you require any additional information. 

PA 126/320/002, 004-007. PA Holder: Clonmel Healthcare Ltd, Clonmel, Co Tipperary. Date prepared: February 2022. 2022/ADV/LEN/031H. 

ADVERTISMENT

Latest

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT

Latest Issue

Irish Pharmacist June 2024

Irish Pharmacist June 2024. Volume 25 | Issue 6 | June 2024. Read the latest issue of Irish Pharmacist here…

Read

OTC Update Spring 2024

Spring 2024 | Issue 1 | Volume 18. Read the latest issue of OTC Update here.

Read

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT